As bioprocessing becomes more connected and data-driven, can protein quantitation move beyond the lab to deliver more actionable insights where they matter most?

How can downstream processing keep pace with increasingly complex biologics? Greater selectivity and process intensification could help build more flexible and efficient purification strategies

Could digital integration and smarter workflows transform the NHS’s pre-analytical process and improve patient safety?

As regulators increasingly focus on individual accountability, can manufacturing leaders afford to treat data governance as a back-office function?

Will the next generation of blockbuster therapies be won by science alone or by the speed of manufacturing execution?

A wave of small interfering RNA therapeutics targeting prevalent cardiometabolic diseases is anticipated to drive active pharmaceutical ingredients demand beyond the scale that existing manufacturing models were designed to support. Meeting this demand will require coordinated advances in manufacturing technology and supply chain structure alongside substantial investment in global production capacity

In the fast-paced, competitive world of generics manufacturing, processes such as integrated dissolution-absorption testing can mean the difference between first to market and obscurity

Pharmaceutical manufacturers are rethinking operational resilience as connected systems, automation and infrastructure dependencies play a larger role in production. Continuity now depends on more than equipment performance. It also depends on how well companies coordinate technology, workforce oversight and compliance across increasingly integrated manufacturing environments

Miriam Krechlok from Mettler-Toledo Product Inspection speaks to IPT about advanced contamination detection systems and how these are utilised in pharma manufacturing to ensure seamless and good manufacturing practice-compliant products

How are life sciences organisations embracing new technologies to help develop soft skills, hopefully mitigating issues seen in the pharma manufacturing sector?

The future of aseptic pharmaceutical manufacturing is gloveless, but what might sound like a bold vision is already turning into reality today

Early-phase development has always required urgency. Today, that urgency is shaped by a more complex set of pressures than ever before. Competitive intensity, milestone-driven financing structures and expanding regulatory expectations are redefining how biotech and virtual pharma companies approach the earliest stages of development.